MedTrace Logo

A Trial of Memantine as Symptomatic Treatment for Early Huntington Disease

NCT01458470 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2020-01-13

No results posted yet for this study

Summary

Huntington disease is characterized by difficulties in movement and thinking. Psychological disturbances including irritability, aggression, loss of interest, depressed mood, obsessions and compulsions, also represent common symptoms of HD. These symptoms are distressing both for HD patients and their caregivers, contribute to the loss of ability to carry out activities of daily living, and present a major treatment challenge for physicians. The goal of this study is to determine the effect of memantine on movement, thinking and emotional difficulties in HD patients. Memantine is a medication originally approved for the treatment of aggression and agitation in patients with moderate-to-severe Alzheimer's disease (AD), which has also recently been shown to improve the behavioural and neuropathological symptoms in a mouse model of Huntington Disease (HD).

Conditions

  • Huntington Disease

Interventions

DRUG

Memantine

oral tablet, 1 BID, 24 weeks

OTHER

Placebo

oral tablet, 1 BID, 24 weeks

Sponsors & Collaborators

  • Huntington Society of Canada

    collaborator OTHER

  • Huntington Study Group

    collaborator NETWORK

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Blair R. Leavitt, MD,CM,FRCPC · University of British Columbia

  • Michael R. Hayden, MD,ChB,PhD · The University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-09-30
Primary Completion
2012-08-31
Completion
2012-11-30

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01458470 on ClinicalTrials.gov